Abstract
physical properties for oral administration. AZD8186 showed profound pharmacodynamic modulation of p-Akt in PTEN-null PC3 prostate tumour bearing mice after oral administration and showed complete inhibition of tumour growth in the mouse PTEN-deficient PC3 prostate tumour xenograft model. AZD8186 was selected as a clinical candidate for treatment of PTEN-dependent cancers and has recently entered phase I clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
